Cilomilast

General information

Cilomilast is an orally active, potent, selective inhibitor of phosphodiesterase type IV, which was developed for the treatment of chronic obstructive pulmonary disease (COPD). However, a review of its efficacy and safety in five phase III double-blind, parallel-group, randomized, placebo-controlled pivotal studies in over 6000 patients with COPD did not show consistent beneficial effects in a range of clinical and laboratory outcomes to confirm the promising early preclinical data [ ]. The manufacturer therefore terminated the development of cilomilast.